Cancer Risks Associated With <i>BRCA1</i> and <i>BRCA2</i> Pathogenic Variants

DOI Web Site 被引用文献2件
  • Shuai Li
    Center for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia
  • Valentina Silvestri
    Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
  • Goska Leslie
    Center for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
  • Timothy R. Rebbeck
    Harvard T.H. Chan School of Public Health, Boston, MA
  • Susan L. Neuhausen
    Department of Population Sciences, Beckman Research Institute of City of Hope, Duarte, CA
  • John L. Hopper
    Center for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, The University of Melbourne, Parkville, Victoria, Australia
  • Henriette Roed Nielsen
    Department of Clinical Genetics, Odense University Hospital, Odence, Denmark
  • Andrew Lee
    Center for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
  • Xin Yang
    Center for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
  • Lesley McGuffog
    Center for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
  • Michael T. Parsons
    Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
  • Irene L. Andrulis
    Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada
  • Norbert Arnold
    Department of Gynaecology and Obstetrics, University Hospital of Schleswig-Holstein, Campus Kiel, Christian-Albrechts University Kiel, Kiel, Germany
  • Muriel Belotti
    Service de Génétique, Institut Curie, Paris, France
  • Åke Borg
    Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
  • Bruno Buecher
    Service de Génétique, Institut Curie, Paris, France
  • Saundra S. Buys
    Department of Medicine and Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT
  • Sandrine M. Caputo
    Service de Génétique, Institut Curie, Paris, France
  • Wendy K. Chung
    Departments of Pediatrics and Medicine, Columbia University, New York, NY
  • Chrystelle Colas
    Service de Génétique, Institut Curie, Paris, France
  • Sarah V. Colonna
    Department of Medicine and Huntsman Cancer Institute, University of Utah Health, Salt Lake City, UT
  • Jackie Cook
    Sheffield Clinical Genetics Service, Sheffield Children's Hospital, Sheffield, United Kingdom
  • Mary B. Daly
    Department of Clinical Genetics, Fox Chase Cancer Center, Philadelphia, PA
  • Miguel de la Hoya
    Molecular Oncology Laboratory, CIBERONC, Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clinico San Carlos), Madrid, Spain
  • Antoine de Pauw
    Service de Génétique, Institut Curie, Paris, France
  • Hélène Delhomelle
    Service de Génétique, Institut Curie, Paris, France
  • Jacqueline Eason
    Nottingham Clinical Genetics Service, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
  • Christoph Engel
    Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany
  • D. Gareth Evans
    Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Center, Manchester, United Kingdom
  • Ulrike Faust
    Institute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen, Germany
  • Tanja N. Fehm
    Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
  • Florentia Fostira
    Molecular Diagnostics Laboratory, INRASTES, National Center for Scientific Research “Demokritos”, Athens, Greece
  • George Fountzilas
    Aristotle University of Thessaloniki School of Medicine, Thessaloniki, Greece
  • Megan Frone
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD
  • Vanesa Garcia-Barberan
    Molecular Oncology Laboratory, CIBERONC, Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clinico San Carlos), Madrid, Spain
  • Pilar Garre
    Molecular Oncology Laboratory, CIBERONC, Hospital Clinico San Carlos, IdISSC (Instituto de Investigación Sanitaria del Hospital Clinico San Carlos), Madrid, Spain
  • Marion Gauthier-Villars
    Service de Génétique, Institut Curie, Paris, France
  • Andrea Gehrig
    Department of Human Genetics, University Würzburg, Würzburg, Germany
  • Gord Glendon
    Fred A. Litwin Center for Cancer Genetics, Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto, ON, Canada
  • David E. Goldgar
    Department of Dermatology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT
  • Lisa Golmard
    Service de Génétique, Institut Curie, Paris, France
  • Mark H. Greene
    Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD
  • Eric Hahnen
    Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
  • Ute Hamann
    Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany
  • Helen Hanson
    Southwest Thames Regional Genetics Service, St George's Hospital, London, United Kingdom
  • Tiara Hassan
    Breast Cancer Research Programme, Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia
  • Julia Hentschel
    Institute of Human Genetics, University Hospital Leipzig, Leipzig, Germany
  • Judit Horvath
    Institute of Human Genetics, University of Münster, Münster, Germany
  • Louise Izatt
    Clinical Genetics Department, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom
  • Ramunas Janavicius
    Faculty of Medicine, Department of Human and Medical Genetics, Institute of Biomedical Sciences, Vilnius University, Vilnius, Lithuania
  • Yue Jiao
    Genetic Epidemiology of Cancer Team, Inserm U900, Paris, France
  • Esther M. John
    Department of Epidemiology and Population Health, Stanford University School of Medicine, Stanford, CA
  • Beth Y. Karlan
    Department of Obstetrics and Gynecology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA
  • Sung-Won Kim
    Department of Surgery, Daerim Saint Mary's Hospital, Seoul, South Korea
  • Irene Konstantopoulou
    Molecular Diagnostics Laboratory, INRASTES, National Center for Scientific Research “Demokritos”, Athens, Greece
  • Ava Kwong
    Hong Kong Hereditary Breast Cancer Family Registry, Hong Kong
  • Anthony Laugé
    Service de Génétique, Institut Curie, Paris, France
  • Jong Won Lee
    Department of Surgery, Ulsan University College of Medicine and Asan Medical Center, Seoul, South Korea
  • Fabienne Lesueur
    Genetic Epidemiology of Cancer Team, Inserm U900, Paris, France
  • Noura Mebirouk
    Genetic Epidemiology of Cancer Team, Inserm U900, Paris, France
  • Alfons Meindl
    Department of Gynecology and Obstetrics, University of Munich, Campus Großhadern, Munich, Germany
  • Emmanuelle Mouret-Fourme
    Service de Génétique, Institut Curie, Paris, France
  • Hannah Musgrave
    Yorkshire Regional Genetics Service, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
  • Joanne Ngeow Yuen Yie
    Cancer Genetics Service, National Cancer Center, Singapore, Singapore
  • Dieter Niederacher
    Department of Gynecology and Obstetrics, University Hospital Düsseldorf, Heinrich-Heine University Düsseldorf, Düsseldorf, Germany
  • Sue K. Park
    Department of Preventive Medicine, Seoul National University College of Medicine, Seoul, South Korea
  • Inge Sokilde Pedersen
    Molecular Diagnostics, Aalborg University Hospital, Aalborg, Denmark
  • Juliane Ramser
    Division of Gynaecology and Obstetrics, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany
  • Susan J. Ramus
    Faculty of Medicine, School of Women's and Children's Health, University of NSW Sydney, Sydney, New South Wales, Australia
  • Johanna Rantala
    Clinical Genetics, Karolinska Institutet, Stockholm, Sweden
  • Muhammad U. Rashid
    Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany
  • Florian Reichl
    Department of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
  • Julia Ritter
    Institute of Medical and Human Genetics, Charité–Universitätsmedizin Berlin, Berlin, Germany
  • Andreas Rump
    Faculty of Medicine Carl Gustav Carus, Institute for Clinical Genetics, TU Dresden, Dresden, Germany
  • Marta Santamariña
    Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain
  • Claire Saule
    Service de Génétique, Institut Curie, Paris, France
  • Gunnar Schmidt
    Institute of Human Genetics, Hannover Medical School, Hannover, Germany
  • Rita K. Schmutzler
    Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
  • Leigha Senter
    Clinical Cancer Genetics Program, Division of Human Genetics, Department of Internal Medicine, The Comprehensive Cancer Center, The Ohio State University, Columbus, OH
  • Saba Shariff
    West Midlands Regional Genetics Service, Birmingham Women's Hospital Healthcare NHS Trust, Birmingham, United Kingdom
  • Christian F. Singer
    Department of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
  • Melissa C. Southey
    Precision Medicine, School of Clinical Sciences at Monash Health, Monash University, Clayton, Victoria, Australia
  • Dominique Stoppa-Lyonnet
    Service de Génétique, Institut Curie, Paris, France
  • Christian Sutter
    Institute of Human Genetics, University Hospital Heidelberg, Heidelberg, Germany
  • Yen Tan
    Department of OB/GYN and Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria
  • Soo Hwang Teo
    Breast Cancer Research Programme, Cancer Research Malaysia, Subang Jaya, Selangor, Malaysia
  • Mary Beth Terry
    Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY
  • Mads Thomassen
    Department of Clinical Genetics, Odense University Hospital, Odence, Denmark
  • Marc Tischkowitz
    Program in Cancer Genetics, Departments of Human Genetics and Oncology, McGill University, Montréal, QC, Canada
  • Amanda E. Toland
    Department of Cancer Biology and Genetics, The Ohio State University, Columbus, OH
  • Diana Torres
    Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany
  • Ana Vega
    Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain
  • Sebastian A. Wagner
    Department of Medicine, Hematology/Oncology, Goethe-University Frankfurt, Frankfurt, Germany
  • Shan Wang-Gohrke
    Department of Gynaecology and Obstetrics, University Hospital Ulm, Ulm, Germany
  • Barbara Wappenschmidt
    Center for Familial Breast and Ovarian Cancer, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
  • Bernhard H. F. Weber
    Institute of Human Genetics, University Regensburg, Regensburg, Germany
  • Drakoulis Yannoukakos
    Molecular Diagnostics Laboratory, INRASTES, National Center for Scientific Research “Demokritos”, Athens, Greece
  • Amanda B. Spurdle
    Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
  • Douglas F. Easton
    Center for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom
  • Georgia Chenevix-Trench
    Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
  • Laura Ottini
    Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy
  • Antonis C. Antoniou
    Center for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom

抄録

<jats:sec><jats:title>PURPOSE</jats:title><jats:p> To provide precise age-specific risk estimates of cancers other than female breast and ovarian cancers associated with pathogenic variants (PVs) in BRCA1 and BRCA2 for effective cancer risk management. </jats:p></jats:sec><jats:sec><jats:title>METHODS</jats:title><jats:p> We used data from 3,184 BRCA1 and 2,157 BRCA2 families in the Consortium of Investigators of Modifiers of BRCA1/2 to estimate age-specific relative (RR) and absolute risks for 22 first primary cancer types adjusting for family ascertainment. </jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p> BRCA1 PVs were associated with risks of male breast (RR = 4.30; 95% CI, 1.09 to 16.96), pancreatic (RR = 2.36; 95% CI, 1.51 to 3.68), and stomach (RR = 2.17; 95% CI, 1.25 to 3.77) cancers. Associations with colorectal and gallbladder cancers were also suggested. BRCA2 PVs were associated with risks of male breast (RR = 44.0; 95% CI, 21.3 to 90.9), stomach (RR = 3.69; 95% CI, 2.40 to 5.67), pancreatic (RR = 3.34; 95% CI, 2.21 to 5.06), and prostate (RR = 2.22; 95% CI, 1.63 to 3.03) cancers. The stomach cancer RR was higher for females than males (6.89 v 2.76; P = .04). The absolute risks to age 80 years ranged from 0.4% for male breast cancer to approximately 2.5% for pancreatic cancer for BRCA1 carriers and from approximately 2.5% for pancreatic cancer to 27% for prostate cancer for BRCA2 carriers. </jats:p></jats:sec><jats:sec><jats:title>CONCLUSION</jats:title><jats:p> In addition to female breast and ovarian cancers, BRCA1 and BRCA2 PVs are associated with increased risks of male breast, pancreatic, stomach, and prostate (only BRCA2 PVs) cancers, but not with the risks of other previously suggested cancers. The estimated age-specific risks will refine cancer risk management in men and women with BRCA1/2 PVs. </jats:p></jats:sec>

収録刊行物

被引用文献 (2)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ